Business Wire · PIK · November 9, 2026

Faeth Reports Positive Preliminary Phase 2 Topline Results from the PIK-201 Trial Evaluating PIKTOR in Combination with Paclitaxel in Patients with Advanced Endometrial Cancer

Get the app for more

Explore stock news, insights and company research.